NCT06064838Completed
Effects of Cacao Flavonoids in Long COVID-19 Patients (FLALOC)
Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue (FLALOC)
Source: ClinicalTrials.gov · Last updated 1 Oct 2024
Brief summary (registry, in English)
The study use a triple blind, placebo-controlled design enrolling male and female subjects between 30-70 yo to evaluate the effect of daily consumption of a cacao supplement on inflammation, endothelial damage, handgrip strength, fatigue scale and quality of life.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 46 (actual)
- First submitted
- 2 Oct 2023
- Start date
- 1 Aug 2023
- Primary completion date
- 1 Aug 2024
- Lead sponsor
- Guillermo Ceballos Reyes
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06064838
What you commit to
- Study type: Interventional
- Participants enrolled: 46
- From 1 Aug 2023 to the primary completion date, 1 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy or intolerance caused by active ingredients
- chronic liver disease
- chronic kidney disease
Other
- Pregnancy or lactation
- BMI \>35
Who the study is looking for
- Post-COVID-19 patients, at least 6 months after symptom onset
- Chronic fatigue
Age in the registry: 30 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| C.E. Indianilla Coordinator of this site? Confirm its status | Mexico City | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.